{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:15:37Z","timestamp":1790082937341,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017412","name":"BD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poly-4-hydroxybutyrate (P4HB) scaffolds are increasingly used to reinforce soft tissue during implant-based reconstruction after mastectomy. P4HB undergoes hydrolytic degradation to a natural metabolite, 4-hydroxybutyrate (4HB). Understanding the direct effects of 4HB on cancer cells is essential for assessing the oncologic safety of P4HB scaffolds used in breast reconstruction surgery. The aim of this study was to evaluate the effects of sodium 4-hydroxybutyrate (Na4HB) on multiple, relevant human breast cancer and epithelial cell types using a panel of well-established in vitro assays aligned with several hallmarks of cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>First, the clinically relevant tissue concentration of 4HB was determined via a rabbit model to quantify 4HB in the peri-implant tissue of P4HB scaffolds. Second, human breast cell types, including non-malignant HMEC and MCF-10A, and cancerous MCF-7, BT-474 and MDA-MB-231, were exposed to Na4HB at up to 10X the clinically relevant tissue concentration. Cells were then evaluated for cancer related phenotypes: metabolic activity (MTT assay), proliferation (BrdU assay), migration (Scratch and Transwell assays), and colony formation (soft agar assays). Specific inhibitory control compounds for each assay were included to confirm assay performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The average peri-implant concentration of 4HB was found to be 163 \u00b5M after a simulated 1-year implantation in a rabbit model. Across the five assays and all three Na4HB concentrations, ranging from below to over 10X the peri-implant level (70, 350, 1750 \u00b5M), there was no statistically significant increase in any cancer-related phenotype including metabolic activity, proliferation, migration and colony formation in either malignant or non-malignant cell types compared to controls treated with either the PBS vehicle or sodium acetate as determined by one-way ANOVA followed by Tukey\u2019s multiple comparison test (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This comprehensive, in vitro evaluation suggests that 4HB does not modify growth or activity of malignant or non-malignant breast cells at concentrations up to 10X the peri-implant level. While these findings suggest that 4HB released from degrading P4HB Scaffolds is unlikely to promote oncogenic behavior in vitro, further co-culture systems, in vivo studies and long-term clinical data can be used to further assess the oncologic safety in breast reconstruction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02234-7","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:54:03Z","timestamp":1771062843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["4-Hydroxybutyrate (4HB) released from poly-4-hydroxybutyrate scaffolds does not impact hallmark phenotypes of cancer in malignant or non-malignant breast cells"],"prefix":"10.1186","volume":"28","author":[{"given":"Sakib F.","family":"Elahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela J.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remya","family":"Kommeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline C.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsey","family":"Reavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Catalina","family":"Ardila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Badylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"2234_CR1","unstructured":"American Society of Plastic Surgeons. 2024 Plastic Surgery Statistics Report [Internet]. 2024. Available from: https:\/\/www.plasticsurgery.org\/documents\/news\/statistics\/2024\/plastic-surgery-statistics-report-2024.pdf"},{"issue":"2","key":"2234_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-018-5018-1","volume":"173","author":"M Jonczyk","year":"2019","unstructured":"Jonczyk M, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. Breast Cancer Res Treat. 2019;173(2):267\u201374.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2234_CR3","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1097\/PRS.0000000000010575","volume":"153","author":"FD Graziano","year":"2024","unstructured":"Graziano FD, Plotsker EL, Rubenstein RN, Haglich K, Stern CS, Matros E, et al. National trends in acellular dermal matrix utilization in immediate breast reconstruction. Plast Reconstr Surg. 2024;153(1):E25.","journal-title":"Plast Reconstr Surg"},{"issue":"S1","key":"2234_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/SAP.0000000000002339","volume":"85","author":"AS Levy","year":"2020","unstructured":"Levy AS, Bernstein JL, Xia JJ, Otterburn DM. Poly-4-Hydroxybutyric acid mesh compares favorably with acellular dermal matrix in tissue Expander\u2013Based breast reconstruction. Ann Plast Surg. 2020;85(S1):S2\u20137.","journal-title":"Ann Plast Surg"},{"issue":"1","key":"2234_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/PRS.0000000000010914","volume":"154","author":"K Movassaghi","year":"2024","unstructured":"Movassaghi K, Gilson A, Stewart CN, Cusic J, Movassaghi A. Prepectoral two-stage implant-based breast reconstruction with Poly-4-Hydroxybutyrate for pocket control without the use of acellular dermal matrix: a 4-year review. Plast Reconstr Surg. 2024;154(1):15.","journal-title":"Plast Reconstr Surg"},{"key":"2234_CR6","doi-asserted-by":"crossref","unstructured":"Van Natta BW, Pineda Molina C, Antonelli V, Hussey GS, Badylak SF. Histomorphologic outcomes of GalaFLEX scaffold used in breast surgery: clinical Follow-up from 6 weeks to 63 months. Aesthetic Surg J. 2025.","DOI":"10.1093\/asj\/sjaf100"},{"key":"2234_CR7","doi-asserted-by":"crossref","unstructured":"Bai J, Ferenz S, Fracol M, Kim JY. Revision breast reconstruction with biologic or synthetic mesh: an analysis of postoperative capsular contracture rates. Aesthetic Surg J Open Forum. 2024;6.","DOI":"10.1093\/asjof\/ojae035"},{"key":"2234_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/scitranslmed.aat7973","volume":"11","author":"MT Wolf","year":"2019","unstructured":"Wolf MT, Ganguly S, Wang TL, Anderson CW, Sadtler K, Narain R, et al. A biologic scaffold\u2013associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy. Sci Transl Med. 2019;11:477.","journal-title":"Sci Transl Med"},{"key":"2234_CR9","doi-asserted-by":"crossref","unstructured":"Williams SF, Martin DP, Moses AC. The history of GalaFLEX P4HB scaffold. Aesthetic Surg J. 2016;(Suppl):S33\u201342.","DOI":"10.1093\/asj\/sjw141"},{"issue":"9","key":"2234_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.neurobiolaging.2006.06.008","volume":"28","author":"M Mamelak","year":"2007","unstructured":"Mamelak M. Alzheimer\u2019 s disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging. 2007;28(9):1340\u201360.","journal-title":"Neurobiol Aging"},{"key":"2234_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neuroscience.2013.12.067","volume":"263","author":"K Wendt","year":"2014","unstructured":"Wendt K, Patte-Mensah U-L, Eckert S, et al. Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death. Neuroscience. 2014;263:203\u201315.","journal-title":"Neuroscience"},{"issue":"1","key":"2234_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF03190843","volume":"14","author":"K Gibson","year":"1989","unstructured":"Gibson K, Nyhan W. Metabolism of [U-14\u00a0C]-4-hydroxybutyric acid to intermediates of the Tricarboxylic acid cycle in extracts of rat liver and kidney mitochondria. Eur J Drug Metab Pharmacokinet. 1989;14(1):61\u201370.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9\u201310","key":"2234_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1089\/ten.tea.2018.0377","volume":"25","author":"C Pineda Molina","year":"2019","unstructured":"Pineda Molina C, Hussey GS, Eriksson J, Shulock MA, C\u00e1rdenas Bonilla LL, Giglio RM, et al. 4-Hydroxybutyrate promotes endogenous antimicrobial peptide expression in macrophages. Tissue Eng Part A. 2019;25(9\u201310):693\u2013706.","journal-title":"Tissue Eng Part A"},{"key":"2234_CR14","doi-asserted-by":"crossref","unstructured":"Zare-Zardini H, Saberian E, Jen\u010da A, Ghanipour-Meybodi R, Jen\u010da A, Petr\u00e1\u0161ov\u00e1 A et al. From defense to offense: antimicrobial peptides as promising therapeutics for cancer. Front Oncol. 2024;14.","DOI":"10.3389\/fonc.2024.1463088"},{"issue":"3","key":"2234_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s13273-023-00378-7","volume":"20","author":"J Huang","year":"2024","unstructured":"Huang J, Chen X, Lin H, Chen X. \u03b2-hydroxybutyrate impairs nasopharyngeal carcinoma cell aggressiveness via histone deacetylase 4 Inhibition. Mol Cell Toxicol. 2024;20(3):629\u201340.","journal-title":"Mol Cell Toxicol"},{"issue":"23","key":"2234_CR16","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/s41388-023-02700-y","volume":"42","author":"T Mao","year":"2023","unstructured":"Mao T, Qin F, Zhang M, Li J, Li J, Lai M. Elevated serum \u03b2-hydroxybutyrate, a circulating ketone metabolite, accelerates colorectal cancer proliferation and metastasis via ACAT1. Oncogene. 2023;42(23):1889\u201399.","journal-title":"Oncogene"},{"key":"2234_CR17","doi-asserted-by":"crossref","unstructured":"Deeken CR, Matthews BD. Characterization of the mechanical Strength, resorption Properties, and histologic characteristics of a fully absorbable material (Poly-4-hydroxybutyrate\u2014PHASIX Mesh) in a Porcine model of hernia repair. Report No.: edsbas; 2013 May.","DOI":"10.1155\/2013\/238067"},{"issue":"2","key":"2234_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jss.2013.03.044","volume":"184","author":"DP Martin","year":"2013","unstructured":"Martin DP, Badhwar A, Shah DV, Rizk S, Eldridge SN, Gagne DH, et al. Characterization of poly-4-hydroxybutyrate mesh for hernia repair applications. J Surg Res. 2013;184(2):766\u201373.","journal-title":"J Surg Res"},{"key":"2234_CR19","first-page":"13","volume":"3","author":"H Pineda Molina, Giglio, Gandhi, Sica","year":"2019","unstructured":"Pineda Molina, Giglio, Gandhi, Sicari, Londono H, et al. Comparison of the host macrophage response to synthetic and biologic surgical meshes used for ventral hernia repair. J Immunol Regen Med. 2019;3:13\u201325.","journal-title":"J Immunol Regen Med"},{"issue":"1\u20132","key":"2234_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1\u20132):55\u201363.","journal-title":"J Immunol Methods"},{"issue":"2","key":"2234_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0003-2697(90)90310-6","volume":"185","author":"D Muir","year":"1990","unstructured":"Muir D, Varon S, Manthorpe M. An enzyme-linked immunosorbent assay for bromodeoxyuridine incorporation using fixed microcultures. Anal Biochem. 1990;185(2):377\u201382.","journal-title":"Anal Biochem"},{"issue":"3","key":"2234_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1084\/jem.115.3.453","volume":"115","author":"S Boyden","year":"1962","unstructured":"Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Experimental Med the. 1962;115(3):453\u201366.","journal-title":"J Experimental Med the"},{"issue":"1","key":"2234_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mrrev.2012.08.001","volume":"752","author":"N Kramer","year":"2013","unstructured":"Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschl\u00e4ger M, et al. In vitro cell migration and invasion assays. Mutat Res. 2013;752(1):10\u201324.","journal-title":"Mutat Res"},{"key":"2234_CR24","doi-asserted-by":"crossref","unstructured":"Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK et al. The soft agar colony formation assay. J Vis Exp. 2014;(92):E51998.","DOI":"10.3791\/51998"},{"key":"2234_CR25","unstructured":"International Council for Harmonisation (ICH), U.S. Food and drug administration (FDA). ICH S6 (R1) addendum: preclinical safety evaluation of biotechnology-derived pharmaceuticals part II, Sect.\u00a03.1. 2012; Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/S6-(R1-Addendum--Preclinical-Safety-Evaluation-of-Biotechnology---Derived-Pharmaceuticals.pdf"},{"key":"2234_CR26","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Y\u00e9pez EA, Ayala-Sumuano J-T, Reveles-Espinoza AM, Meza I, Toillon R-A. Selection of a MCF-7 breast cancer cell subpopulation with high sensitivity to IL-1\u03b2: characterization of and correlation between morphological and molecular changes leading to increased invasiveness. Int J Breast Cancer. 2012;2012.","DOI":"10.1155\/2012\/609148"},{"issue":"5","key":"2234_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"5","key":"2234_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/j.1471-4159.1981.tb04689.x","volume":"37","author":"T Nelson","year":"1981","unstructured":"Nelson T, Kaufman E, Kline J, Sokoloff L. The extraneural distribution of \u03b3-Hydroxybutyrate. J Neurochem. 1981;37(5):1345\u20138.","journal-title":"J Neurochem"},{"issue":"5","key":"2234_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/asj\/sjy022","volume":"38","author":"WP Adams","year":"2018","unstructured":"Adams WP, Baxter R, Glicksman C, Mast BA, Tantillo M, Van Natta BW. The use of Poly-4-Hydroxybutyrate (P4HB) scaffold in the ptotic breast: a multicenter clinical study. Aesthetic Surg J. 2018;38(5):502\u201318.","journal-title":"Aesthetic Surg J"},{"issue":"6S","key":"2234_CR30","doi-asserted-by":"publisher","first-page":"S466","DOI":"10.1097\/SAP.0000000000003482","volume":"90","author":"Y Chen","year":"2023","unstructured":"Chen Y, Wang ML, Black GG, Bernstein JL, Chinta M, Otterburn DM. Timeline and incidence of postoperative complications in prepectoral, dual-plane, and total submuscular alloplastic reconstruction with and without biosynthetic scaffold usage. Ann Plast Surg. 2023;90(6S):S466\u201371.","journal-title":"Ann Plast Surg"},{"issue":"5","key":"2234_CR31","doi-asserted-by":"publisher","first-page":"E5821","DOI":"10.1097\/GOX.0000000000005821","volume":"12","author":"RD Rehnke","year":"2024","unstructured":"Rehnke RD, Clarke JM, Goodrum AJ, Badylak SF. Absorbable biosynthetic scaffolds in place of silicone for breast reconstruction: a 9-Year experience with 53 patients. Plast Reconstr Surg Glob Open. 2024;12(5):E5821.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"8","key":"2234_CR32","doi-asserted-by":"publisher","first-page":"E6031","DOI":"10.1097\/GOX.0000000000006031","volume":"12","author":"S Ferenz","year":"2024","unstructured":"Ferenz S, Bai J, Fracol M, Kim JYS. A comparison of capsular contracture rates after immediate Implant-based breast reconstruction using biologic versus synthetic mesh. Plast Reconstr Surg Glob Open. 2024;12(8):E6031.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"4","key":"2234_CR33","doi-asserted-by":"publisher","first-page":"E409","DOI":"10.1097\/PRS.0000000000007172","volume":"146","author":"RD Rehnke","year":"2020","unstructured":"Rehnke RD, Schusterman MA, Clarke JM, Price BC, Waheed U, Debski RE, et al. Breast reconstruction using a three-dimensional absorbable mesh scaffold and autologous fat grafting: a composite strategy based on tissue-engineering principles. Plast Reconstr Surg. 2020;146(4):E409.","journal-title":"Plast Reconstr Surg"},{"key":"2234_CR34","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1097\/PRS.0000000000009520","volume":"150","author":"S Sigalove","year":"2022","unstructured":"Sigalove S, O\u2019Rorke E, Maxwell GP, Gabriel A. Evaluation of the safety of a GalaFLEX-AlloDerm construct in prepectoral breast reconstruction. Plast Reconstr Surg. 2022;150:S75\u201381.","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"2234_CR35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/asj\/sjae145","volume":"44","author":"NR Sinclair","year":"2024","unstructured":"Sinclair NR, Adams WPJ. Long-term outcomes of Poly-4-Hydroxybutyrate (P4HB) in aesthetic breast surgery. Aesthetic Surg J. 2024;44(12):1293\u20139.","journal-title":"Aesthetic Surg J"},{"issue":"5","key":"2234_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/SAP.0000000000004233","volume":"94","author":"M Diffley","year":"2025","unstructured":"Diffley M, Tang A, Sawar K, Al-Saghir T, Gonte MR, Hall J, et al. Comparative postoperative complications of acellular dermal matrix and mesh use in prepectoral and subpectoral one-stage direct to implant reconstruction: a retrospective cohort study. Ann Plast Surg. 2025;94(5):521\u20137.","journal-title":"Ann Plast Surg"},{"issue":"19","key":"2234_CR37","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1002\/cncr.34393","volume":"128","author":"CA Bargon","year":"2022","unstructured":"Bargon CA, Young-Afat DA, Ikinci M, Braakenburg A, Rakhorst HA, Mureau MAM, et al. Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction\u2014a systematic review and meta\u2010analysis. Cancer. 2022;128(19):3449\u201369.","journal-title":"Cancer"},{"issue":"2","key":"2234_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00238-021-01868-4","volume":"45","author":"D Casella","year":"2022","unstructured":"Casella D, Kaciulyte J, Resca L, Lo Torto F, Luridiana G, Restaino V, et al. Looking beyond the prepectoral breast reconstruction experience: a systematic literature review on associated oncological safety and cancer recurrence incidence. Eur J Plast Surg. 2022;45(2):223\u201331.","journal-title":"Eur J Plast Surg"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02234-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02234-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02234-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:16:36Z","timestamp":1781633796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02234-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02234-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the study was provided under IACUC protocol number 23790053 addressing the use of animals in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SFE, DPM, ACM, and DCA report employment by Becton, Dickinson and Company (BD) during the conduct of this study, as well as outside of the current work. SFE and DPM hold shares in the company. LR is a consultant of BD. SB conducts studies at the University of Pittsburgh sponsored by BD. All cell lines were obtained from ATCC and used in accordance with institutional biosafety regulations. No new human tissue was used in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}